LEO Pharma is a leader in medical dermatology with a robust R&D pipeline across a wide range of therapies.

Founded in 1908, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in more than 130 countries.

LEO Pharma has a clear strategy and ambition to be a global leader in medical dermatology by expanding its leading branded topical dermatology franchise and developing a deep, innovative pipeline.

As an active minority owner in LEO Pharma and partner to the company’s majority owner the LEO Foundation, Nordic Capital will support LEO Pharma on its journey to strengthening its global leadership in medical dermatology and help accelerate innovation and growth.


Sector Icon


Key Information

Revenues Icon

Revenues 2021*

EUR 1,370 million

Employees Icon



Ownership Icon


Nordic Capital Fund X (minority shareholding)

Head Office Icon

Head office

Ballerup, Denmark

Investment Icon

Investment date